Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
ZIOPHARM Oncology, Inc. ZIOP
$0.87
На 13:45, 16 марта 2023
Ранг: 3
Ключевые показатели
-
Marketcap
208123810.00000000
-
week52high
5.95
-
week52low
0.76
-
Revenue
0
-
P/E TTM
-2
-
Beta
1.68677100
-
EPS
-0.41900000
-
Last Dividend
0.00000000
-
Next Earnings Date
23 февр 2022 г. в 05:00
Описание компании
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
Grading company | New grade | Previous grade | Recommendation date |
---|---|---|---|
Raymond James | Market Perform | Market Perform | 09 ноя 2021 г. |
Raymond James | Market Perform | Outperform | 10 авг 2021 г. |
Raymond James | Outperform | Outperform | 07 мая 2021 г. |
Jefferies | Hold | Buy | 12 мар 2021 г. |
HC Wainwright & Co. | Neutral | Buy | 01 мар 2021 г. |
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Insider Summary
Insider Summary
Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
---|---|---|---|---|
Lackey Melinda | A | 185000 | 185000 | 15 сент 2022 г. |
Wong Michael | A | 50000 | 50000 | 15 сент 2022 г. |
Srivastava Abhishek K | A | 25000 | 25000 | 15 сент 2022 г. |
Deniger Drew | A | 305000 | 305000 | 15 сент 2022 г. |
Boyle Kevin S. Sr. | D | 866250 | 18750 | 30 авг 2022 г. |
Srivastava Abhishek K | A | 250000 | 250000 | 12 авг 2022 г. |
Weis Holger | A | 100000 | 100000 | 22 июн 2022 г. |
Weis Holger | A | 160167 | 40000 | 22 июн 2022 г. |
Bowden Christopher | A | 100000 | 100000 | 22 июн 2022 г. |
Bowden Christopher | A | 44167 | 40000 | 22 июн 2022 г. |
Свежие комментарии
Свежие комментарии